Author

Mehmet Samur

Harvard UniversityORCID 0000-0002-9978-5682Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Assay:whole-genome sequencing· 2 Approach:benchmark study· 1

Frequent Co-Authors

Nikhil C. MunshiiD· 3 shared Alessandro LaganàiD· 2 shared Adam Samuel SperlingiD· 1 shared Ajay K. NookaiD· 1 shared Alex Gout· 1 shared Angela Hamblin· 1 shared Anjan ThakurtaiD· 1 shared Chaitanya R. AcharyaiD· 1 shared

Activity by Year

2018-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Nikhil C. MunshiORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Synthetic lethality of p97 inhibition and PSMC2-overexpressionovercomes bortezomib resistance in multiple myeloma

James J Ignatz-Hoover, Ernest Ricky Chan, Ehsan Malek, John D'Cruz, Nida Mubin, Wei Huang, Derek J Taylor, Mehmet Samur, Nikhil C. Munshi, Kenneth C. Anderson, James Joseph Driscoll

This study identifies PSMC2 overexpression as a driver of bortezomib resistance in multiple myeloma and shows that combining p97 inhibition with bortezomib overcomes this resistance.

bioRxiv · Nov 3, 2026 · PreprintCancer Biology

Sequential acquisition of 1p31.1-p12 LOH and 1q Gain is a common double-hit event in relapsed/refractory myeloma

Naser Ansari‐Pour, Sarah Gooding, Mohammad H. Kazeroun, Seyed Alireza Hasheminasab, Evie Fitzsimons, Selina J Chavda, Alessandro Laganà, Erin Flynt, Udo C. T. Oppermann, Karthik Ramasamy, Kwee Yong, Angela Hamblin, Jill Corre, Hervé Avet‐Loiseau, Nikhil C. Munshi, , Anjan Thakurta

The paper identifies a therapy-driven genomic double-hit (1pCEN LOH and 1q gain) in relapsed/refractory myeloma, associated with poor prognosis and clonal expansion.

bioRxiv · May 21, 2026 · PreprintCancer Biology

Longitudinal multi-omic profiling uncovers immune escape and predictors of response in multiple myeloma

Denis J. Ohlstrom, William Pilcher, Marina E. Michaud, Chaitanya R. Acharya, Sarthak Satpathy, Edgar Gonzalez‐Kozlova, Reyka G. Jayasinghe, Katherine E. Ferguson, Hope Mumme, Shivani Nanda, Yizhe Song, Sowmitri Karthikeya Mantrala, Dimitra Karagkouni, Jessica Schulman, Nick Pabustan, , Manoj Bhasin

This study uses longitudinal multi-omic profiling to identify immune escape mechanisms and predictors of response in multiple myeloma.

bioRxiv · May 27, 2025 · PreprintCancer Biology

Widespread intronic polyadenylation diversifies immune cell transcriptomes

Irtisha Singh, Shih‐Han Lee, Adam Samuel Sperling, Mehmet Samur, Yu‐Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Christine Mayr, Christina S. Leslie

The paper identifies widespread intronic polyadenylation (IpA) events in immune cells and shows their role in transcriptome diversification and potential functional consequences.

Nature Communications · Apr 24, 2018Peer-reviewedGenomics